Similarly, Fletcher and colleagues reported that erlotinib induced expression of IL6 and other proinflammatory cytokines in HNSCC cells, and that combining erlotinib with the IL-6Rα-targeted antibody TCZ led to substantial reductions in tumor volumes compared to treatment with either drug alone in mouse xenograft models [44]. Here, IL6 is linked to head and neck squamous cell carcinoma.